comprehensive -WSS

comprehensive

author：Wikipedia 2025-09-29 22:53:20 - browse：7811

U.S. Sen. Bernie Sanders sets his hands on two chairs as two people set up a board displaying a "price of drugs" chart behind him — politics coverage from STAT — Sen. Bernie Sanders has used his leadership of a Senate committee to pressure drugmakers to lower their prices. Kevin Dietsch/Getty Images

WASHINGTON — Bernie Sanders is figuring out just how far bullying drugmakers can take him.

For more than a year, Sanders has used his perch atop the Senate health committee to haul the CEOs of pharmaceutical companies that make insulin, vaccines, and more before the panel with progressively more ambitious demands related to their pricing. After a few victories he’s claimed — experts say some credit is deserved, but the full story is a bit more complicated — he’s now progressed to demanding that Novo Nordisk cut its price for its novel, wildly popular diabetes and weight-loss drugs.

Sanders (I-Vt.) is testing the limits of the powers of a Senate chairman with little hope of advancing his policy agenda legislatively. He’s threatened subpoenas, held a prominent nominee hostage, and initiated investigations to get his way. It’s a sharp departure from the modest, bipartisan ambitions that more disciplined, discreet leaders of the committee have taken in years past, and sets the bar for how much can be accomplished using the full extent of the bully pulpit.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Ultragenyx gene therapy for rare liver ailment succeeds in late

focus

WSS

DeSantis wants to import drugs. Biden’s FDA blasted his plan

Innovation in antibiotics is ailing. 'Brain drain' may kill it

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

As obesity drug market grows, telehealth companies court payers

Meadows told special counsel he could not recall Trump ever declassifying Mar

Wegovy improves function in certain heart failure patients

focus

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Wikipedia

State Dept. review finds Biden bears some blame for Afghanistan failures

Intellia plays down concerns on accidental germline transmission

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

Drug repurposing or repositioning? The language matters

National associations that represent hospice owe an apology

Medical records are filled with copy

Drugmakers bet big on mRNA for cancer. Why's Biden going in?

George Santos makes 1st court appearance after pleading not guilty to 13 counts

DeSantis wants to import drugs. Biden’s FDA blasted his plan

entertainment

Abortion policy in the spotlight at Republican debate

Change Healthcare can notify patients about the breach, HHS says

At ASCO, AstraZeneca reports strong data for breast cancer drug

BMI, flaws aside, is found to be useful estimate of body fat in youth

How the drug

FDA's Pazdur wants cancer trials to range beyond China alone

focus

leisure time

focus

knowledge